Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2016-06, Vol.30 (6), p.1425-1427
Hauptverfasser:	Eichenauer, D A, Goergen, H, Plütschow, A, Wongso, D, Behringer, K, Kreissl, S, Thielen, I, Halbsguth, T, Bröckelmann, P J, Fuchs, M, Böll, B, von Tresckow, B, Borchmann, P, Engert, A
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1990/291/1556 692/308/2779/109/1941 692/699/1541/1990/291 692/699/67/1059/99 Antibodies Cancer Research Cancer therapies Chemotherapy Critical Care Medicine Development and progression Drug dosages Drug therapy Health aspects Hematology Hodgkin's disease Hodgkin's lymphoma Hypotheses Intensive Internal Medicine letter-to-the-editor Letters to the editor Leukemia Lymphocytes Lymphoma Medicine Medicine & Public Health Mutation Ofatumumab Oncology Pathology Patient outcomes Quality of life Response rates Stem cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!